These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9760694)

  • 41. Therapeutic and chemical developments of cholecystokinin receptor ligands.
    de Tullio P; Delarge J; Pirotte B
    Expert Opin Investig Drugs; 2000 Jan; 9(1):129-46. PubMed ID: 11060666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists.
    Lotti VJ; Cerino DJ; Kling PJ; Change RS
    Life Sci; 1986 Nov; 39(18):1631-8. PubMed ID: 3773639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opposing effects of two CCK(B) agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat.
    Léna I; Simon H; Roques BP; Daugé V
    Neuropharmacology; 1999 Apr; 38(4):543-53. PubMed ID: 10221758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological effects of oxytocin on gastric emptying and intestinal transit of a non-nutritive liquid meal in female rats.
    Wu CL; Hung CR; Chang FY; Pau KY; Wang PS
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Apr; 367(4):406-13. PubMed ID: 12690433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509.
    Hagishita S; Murakami Y; Seno K; Kamata S; Haga N; Konoike T; Kanda Y; Kiyama R; Shiota T; Ishihara Y; Ishikawa M; Shimamura M; Abe K; Yoshimura K
    Bioorg Med Chem; 1997 Aug; 5(8):1695-714. PubMed ID: 9313871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholecystokinin in the inhibition of gastric secretion and gastric emptying in humans.
    Konturek SJ; Kwiecien N; Obtulowicz W; Kopp B; Oleksy J; Rovati L
    Digestion; 1990; 45(1):1-8. PubMed ID: 2340960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
    Irwin N; Montgomery IA; O'Harte FP; Frizelle P; Flatt PR
    Int J Obes (Lond); 2013 Aug; 37(8):1058-63. PubMed ID: 23164696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transient agonist-induced regulation of the cholecystokinin-A and cholecystokinin-B receptor mRNA levels in rat pancreatic acinar AR42J cells.
    Günther R; Carstens OC; Schmidt WE; Fölsch UR
    Pancreatology; 2003; 3(1):47-54. PubMed ID: 12649564
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of cholecystokinin on gastric motility in humans.
    Beglinger C
    Ann N Y Acad Sci; 1994 Mar; 713():219-25. PubMed ID: 8185162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of CCK and its antagonists on gastric emptying.
    Scarpignato C; Varga G; Corradi C
    J Physiol Paris; 1993; 87(5):291-300. PubMed ID: 8298606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.
    Bläker M; Ren Y; Gordon MC; Hsu JE; Beinborn M; Kopin AS
    Mol Pharmacol; 1998 Nov; 54(5):857-63. PubMed ID: 9804620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
    Lotti VJ; Chang RS
    Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of cholecystokinin in the gastric motor response to a meal in horses.
    Lorenzo-Figueras M; Merritt AM
    Am J Vet Res; 2006 Dec; 67(12):1998-2005. PubMed ID: 17144800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Signal transduction pathways mediating CCK-8S-induced gastric antral smooth muscle contraction.
    Si XM; Huang L; Paul SC; An P; Luo HS
    Digestion; 2006; 73(4):249-58. PubMed ID: 16954694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by estradiol in ovariectomized rats.
    Wu CL; Hung CR; Chang FY; Pau KY; Wang PS
    Scand J Gastroenterol; 2002 Oct; 37(10):1133-9. PubMed ID: 12408516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide.
    Cannon JB; Adjei LA; Lu MY; Garren K
    J Drug Target; 1996; 4(2):69-78. PubMed ID: 8894966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
    Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of cholecystokinin agonists on striatal neurons are reduced by acetylcholine.
    Davidowa H; Wetzel K; Vierig G
    Peptides; 1997; 18(4):541-5. PubMed ID: 9210173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile.
    Trivedi BK; Hinton JP
    Pharm Biotechnol; 1998; 11():481-505. PubMed ID: 9760693
    [No Abstract]   [Full Text] [Related]  

  • 60. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ; Armour DR; Berman JM; Birkemo LS; Carr RA; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Head JE; Hirst GC; James MK; Johnson MF; Miller LJ; Queen KL; Rimele TJ; Smith DN; Sugg EE
    J Med Chem; 1996 Jan; 39(2):562-9. PubMed ID: 8558528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.